Post-COVID-19 non-traumatic iliopsoas hematoma: A case report
Journal of Taibah University Medical Sciences
; 18(1):61-64, 2023.
Artigo
em Inglês
| Scopus | ID: covidwho-2238448
ABSTRACT
Background:
Critically ill COVID-19 patients have an elevated risk of experiencing hypercoagulable conditions. Currently, many COVID-19 patients have been administered anticoagulation or antiplatelet therapies to lower the risk of systematic thrombosis. Iliopsoas hematoma is a potentially fatal and rare complication of bleeding disorders or anticoagulation therapy which sometimes grows to become clinically significant. The main purpose of this case review is to emphasize the importance of diagnosing iliopsoas hematomas and the possibility of antiplatelet contribution to its development. Case Presentation We are reporting a rare presentation of non-traumatic iliopsoas hematoma in a non-anticoagulated patient. The patient is a 59-year-old male, with known type-2 diabetes, on oral hypoglycemic medications, 3-weeks post-COVID-19. He had started aspirin 81 mg orally, once daily, to prevent thrombotic events associated with COVID 19 infection, with no anticoagulant use and no other medications. He came in through the ED, presenting with two weeks history of progressive right lower limb weakness in which an iliopsoas hematoma diagnosis was confirmed based on radiological investigation.Conclusion:
The possibility of iliopsoas hematoma should be considered in non-anticoagulated patients with no inherited or acquired coagulation disorders presenting with limb weakness. The link between antiplatelet use in a COVID-19 patient and the development of soft tissue bleeding (e.g., iliopsoas hematoma) must be studied further. © 2022 [The Author/The Authors]
acetylsalicylic acid; antidiabetic agent; C reactive protein; hemoglobin; paracetamol; adult; ambient air; antiplatelet activity; Article; blood pressure; case report; clinical article; decubitus; drug withdrawal; emergency ward; erythrocyte sedimentation rate; examination; fever; follow up; gluteus maximus muscle; heart rate; hematocrit; human; human cell; iliopsoas hematoma; international normalized ratio; limb weakness; long COVID; lower limb; male; middle aged; muscle hematoma; neurologic examination; non insulin dependent diabetes mellitus; nuclear magnetic resonance imaging; oxygen saturation; pain; partial thromboplastin time; platelet count; prothrombin time; psoas muscle; radiodiagnosis; thrombosis; tympanic temperature; Antiplatelet; Case reports; COVID-19; Hematoma; Iliopsoas
Texto completo:
Disponível
Coleções:
Bases de dados de organismos internacionais
Base de dados:
Scopus
Tipo de estudo:
Relato de caso
Tópicos:
Covid persistente
Idioma:
Inglês
Revista:
Journal of Taibah University Medical Sciences
Ano de publicação:
2023
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS